rs2230600 — PTPN13 I1522M

Missense variant in PTPN13 (FAP-1) converting Ile to Met at position 1522; the G allele is associated with impaired tumor-suppressive Fas-mediated apoptosis and elevated squamous cell carcinoma risk

See your personal result for PTPN13

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PTPN13 I1522M — When the Apoptosis Gatekeeper Falters

Every cell in your body carries a molecular self-destruct switch. When that switch is working correctly, damaged or pre-cancerous cells receive a signal through the Fas death receptor11 Fas death receptor
Fas (also called CD95 or APO-1) is a cell-surface receptor that, when bound by Fas ligand on immune cells, triggers a caspase cascade leading to programmed cell death (apoptosis). This is one of the primary mechanisms immune cells use to eliminate virus-infected or pre-malignant cells and quietly eliminate themselves. PTPN13 — also known as FAP-1 (Fas-Associated Phosphatase 1) — encodes a large protein tyrosine phosphatase that sits at this critical junction, regulating how sensitively cells respond to the Fas apoptosis signal. The rs2230600 variant (c.4566A>G, I1522M) is a common missense change in PTPN13's catalytic region that has been associated with elevated risk for multiple squamous cell carcinomas in two independent case-control studies.

The Mechanism

PTPN13 is one of the largest protein tyrosine phosphatases in the human genome — a 2,466-amino-acid protein containing five PDZ domains, a FERM domain, and a C-terminal phosphatase catalytic domain. It acts as a negative regulator of the Fas apoptosis pathway by dephosphorylating phospho-tyrosine 275 on the Fas receptor22 dephosphorylating phospho-tyrosine 275 on the Fas receptor
Tyrosine phosphorylation of Fas at Y275 is required for downstream caspase activation; FAP-1 removes this phosphate group, reducing Fas signaling capacity and the cell's willingness to undergo apoptosis. When PTPN13 activity is reduced or altered, Fas signaling is partially restored and cells become more responsive to immune-mediated elimination.

The p.Ile1522Met substitution changes an isoleucine to a methionine at position 1522 within the large N-terminal regulatory region of the protein. While the precise structural consequence has not been fully characterized at atomic resolution, position 1522 lies within a region that influences protein folding and intermolecular interactions. The variant is thought to subtly alter protein conformation or PDZ domain-mediated interactions, potentially reducing the efficiency with which FAP-1 dephosphorylates Fas and its other substrates including IκBα (a regulator of NF-κB) and STAT1. Separately, elevated FAP-1 expression in cancer cells has been shown to activate NF-κB33 NF-κB
Nuclear factor kappa B — a master transcription factor regulating immune responses, inflammation, and cell survival; its constitutive activation in cancer cells promotes resistance to apoptosis and chemotherapy, creating a dual apoptosis resistance mechanism relevant to the I1522M context.

A 2026 study in Cell Research added an important new dimension: PTPN13 dephosphorylates STAT1, suppressing MHC class I antigen presentation and reducing CD8+ T cell infiltration into tumors. This immune evasion pathway, operating downstream of APC loss in colorectal cancer, positions PTPN13 as a regulator of the tumor immune microenvironment — not just an intracellular apoptosis gatekeeper.

The Evidence

The primary genetic evidence for rs2230600 comes from a US case-control study of head and neck squamous cell carcinoma44 US case-control study of head and neck squamous cell carcinoma
Niu et al., Carcinogenesis 2009; 1,069 SCCHN patients and 1,102 cancer-free non-Hispanic white controls that found the GG genotype carried an odds ratio of 1.89 (95% CI 1.27–2.79) compared to AA. The risk was most pronounced in younger patients (≤57 years), males, never-smokers, current alcohol drinkers, and those with pharyngeal cancers — subgroups where environmental exposure and HPV-independent pathways may matter more, making the genetic contribution proportionally larger. This study also examined two other PTPN13 coding variants (F1356L at rs10033029 and Y2081D at rs989902), of which Y2081D showed a modest independent signal (GT genotype OR 1.26).

A Japanese study55 Japanese study
Mita et al., J Cancer Res Clin Oncol 2010; 569 cancer patients and 819 controls across colorectal, lung, head/neck, and esophageal cancers extended these findings to a broader cancer spectrum. When I1522M and Y2081D were analyzed as a combination genotype, odds ratios for specific cancer subtypes reached 3.36–13.75, suggesting that PTPN13 variants may act additively across multiple tumor types — though the small sample sizes for individual cancer subtypes introduce considerable uncertainty around these estimates.

At the somatic level, PTPN13 is mutated in approximately 26% of colorectal cancers alongside five other tyrosine phosphatase genes, with frameshift and nonsense mutations predominating66 frameshift and nonsense mutations predominating
Wang et al., Science 2004; the study showed wild-type PTPN13 expression suppresses cancer cell proliferation while mutant forms do not. This somatic evidence supports PTPN13 as a bona fide tumor suppressor, contextualizing the germline I1522M variant as a partial, constitutional impairment of the same protective mechanism.

The overall evidence level for I1522M specifically is moderate: two independent case-control studies with consistent directionality, plausible functional mechanism, but no GWAS Catalog entries and no clinical guideline recognition.

Practical Implications

For GG homozygotes, the roughly twofold increased odds ratio for SCCHN is clinically meaningful for individuals with additional risk factors — alcohol use, tobacco, or occupational carcinogen exposures — since these exposures interact with the underlying apoptotic regulation that PTPN13 governs. The cancer types most strongly linked to this variant are squamous cell carcinomas of the head, neck, and upper aerodigestive tract. Awareness of oral cavity symptoms and consistent dental/ENT surveillance is appropriate. For AG heterozygotes, the intermediate risk warrants attention without the same urgency.

Interactions

The PTPN13 variant rs989902 (Y2081D) shows an independent and potentially additive effect with rs2230600 (I1522M) in Japanese cancer cohorts. Individuals carrying risk alleles at both positions may be in a higher-risk category than either variant alone predicts. The rs2230600 G allele may also interact with somatic loss of the second PTPN13 allele (loss of heterozygosity is common in colorectal tumors), making it a potential contributor to acquired cancer progression rather than just inherited risk.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Full PTPN13 activity with intact Fas-mediated apoptosis regulation

You carry two copies of the reference A allele at rs2230600. Your PTPN13 protein is encoded with isoleucine at position 1522 — the ancestral form that maintains the protein's normal structural configuration and phosphatase activity. Cells regulated by this form of FAP-1 retain normal responsiveness to Fas-mediated apoptosis signals, supporting intact immune surveillance of pre-malignant cells. This is the most common genotype globally, carried by approximately 71% of people, and confers no elevated risk at this locus for the squamous cell carcinoma types studied.

AG Intermediate

One copy of the I1522M variant with modestly altered PTPN13 activity

You carry one copy of the G (Met1522) allele. Heterozygotes have one normal and one altered PTPN13 allele; the functional consequence is likely intermediate between AA and GG, though specific heterozygous effect estimates are not well-established in the published literature for this variant. The primary case-control study focused on the GG homozygous comparison; AG heterozygotes showed a trend toward increased squamous cell carcinoma risk that did not reach statistical significance as an independent group. Approximately 25% of people carry this genotype globally.

GG High Risk

Homozygous I1522M variant associated with elevated squamous cell carcinoma risk

The GG genotype places both PTPN13 alleles in the Met1522 configuration. PTPN13 (FAP-1) regulates apoptosis of abnormal cells through the Fas pathway and regulates immune surveillance through STAT1 phosphorylation. A structurally altered FAP-1 protein may impair normal apoptosis of pre-malignant cells in the upper aerodigestive tract — tissues where squamous cell turnover is high and apoptotic surveillance is critical for preventing accumulation of mutations. The protein is highly expressed in skin and several epithelial tissues, consistent with its role as a gatekeeper in squamous epithelium.

FAP-1 overexpression in head and neck SCC has been shown to activate NF-κB and downregulate Fas at the cell surface — dual mechanisms of apoptosis resistance that may be constitutionally primed in GG individuals. The altered I1522M protein may have subtly different regulatory dynamics, potentially altering phosphatase output in squamous epithelia under stress conditions. The evidence is moderate rather than strong — two case-control studies without large-scale GWAS replication — but the biological plausibility of the mechanism supports clinical attention to squamous cell cancer types in GG carriers.